<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Liver transplantation (LTx) is currently an accepted treatment for hereditary transthyretin <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> (h-ATTR) </plain></SENT>
<SENT sid="1" pm="."><plain>However, to optimize the outcome, careful selection of patients is required, since increased mortality compared with that found for nontransplanted historical controls are observed for several groups of h-ATTR patients </plain></SENT>
<SENT sid="2" pm="."><plain>We have noted that malnourished patients and patients with a <z:hpo ids='HP_0003584'>late onset</z:hpo> of the disease especially in combination with findings of <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> are at risk for an increased mortality and morbidity </plain></SENT>
<SENT sid="3" pm="."><plain>Recently detection of different types of amyloid fibrils that appears to be related to the phenotype of the patient may facilitate patient selection for LTx </plain></SENT>
</text></document>